Last updated: February 24, 2026
What is the Drug Associated with NDC 33342-0116?
The National Drug Code (NDC) 33342-0116 is associated with Zolgensma (onasemnogene abeparvovec-xioi). It is a gene therapy designed to treat spinal muscular atrophy (SMA) in pediatric patients under 2 years old.
Market Scope and Demand Dynamics
Target Population
- Approximately 1 in 10,000 live births globally develop SMA, equating to roughly 15,000-20,000 patients annually worldwide.
- In the U.S., about 400-600 new cases are diagnosed annually in children under 2.
Market Penetration
- As of 2022, Zolgensma holds over 80% market share for approved SMA treatments in the U.S.
- Competitors include Spinraza (nusinersen) and Edelvs (risdiplam).
- The drug is approved for patients up to age 2 through the FDA’s accelerated pathway.
Regulatory and Reimbursement Environment
- Approved in over 40 countries.
- Cost reimbursement policies vary; the U.S. industry predominantly relies on private payers and Medicare, with significant negotiation for coverage.
- NICE in the UK and other global health agencies evaluate pricing based on cost-effectiveness and budget impact.
Price Structure and Historical Trends
Price Point
- List price in the U.S. is approximately $2.1 million per treatment (a one-time infusion).
- Price includes manufacturing, delivery, and therapeutic benefits.
Payment Models
- Manufacturers often negotiate payment plans or discounts.
- Pay-for-performance arrangements exist, reflecting outcomes and patient response.
Pricing Trends
- Introduction price set at $2.1 million in late 2019.
- Since launch, no significant price reductions have been announced; discounts and payment pathways alter the effective cost for payers.
Market Projections and Revenue Forecasts
Revenue Drivers
- The primary revenue driver continues to be the eligible patient population.
- Market expansion depends on approvals for broader age groups and new indications like SMA Type 0 or subsequent gene therapies.
Market Growth Estimates
| Year |
Estimated Global Revenue (USD billions) |
Assumptions |
| 2023 |
1.0 |
Current market penetration and ongoing demand |
| 2024 |
1.2 |
Increased approvals, expanded payer coverage |
| 2025 |
1.3 |
Wider global adoption, potential price adjustments |
| 2026 |
1.4 |
Off-label usage, additional SMA indications |
Factors Influencing Growth
- New regulatory approvals for patients aged over 2.
- Consolidation of payer negotiations leading to better reimbursement terms.
- Entry of new gene therapies contesting market share.
Competitive Landscape
| Competitor |
Product |
Status |
Market Share (2022) |
Price (USD) |
Notes |
| Novartis |
Zolgensma |
Market leader |
>80% |
~$2.1 million |
One-time gene therapy |
| Biogen |
Spinraza |
Approved |
~15% |
~$750,000 (per year) |
Intrathecal injections |
| Roche |
Risdiplam |
Approved |
~5% |
Costs vary |
Oral administration |
Price Projections and Outlook
- Price stability expected through 2024 given high manufacturing costs, limited competition, and the lack of immediate alternative therapies.
- Regulatory approvals for expanded indications or age ranges could impact pricing strategies.
- Cost reductions are unlikely absent patent expirations or biosimilar competition, neither relevant for gene therapies due to unique manufacturing.
Key Takeaways
- NDC 33342-0116 (Zolgensma) commands a high price point, remaining near $2.1 million per treatment.
- Revenue projections anticipate modest growth driven by expanding indications and global coverage.
- Competition remains limited; significant price reductions are not expected in the near term.
- Payer negotiations and reimbursement strategies significantly influence actual revenue realization.
- Future pricing dynamics depend on regulatory changes, market expansion, and therapeutic advances.
FAQs
Q1: Are there any upcoming patent expirations for Zolgensma?
A1: Patents are expected to extend through the late 2020s, maintaining exclusivity for early market entrants.
Q2: How does the price of Zolgensma compare internationally?
A2: Prices vary; countries with universal healthcare often negotiate lower prices, typically ranging from $1.5 million to $2.5 million.
Q3: What are the primary factors affecting reimbursement negotiations?
A3: Cost-effectiveness assessments, patient outcomes, and healthcare budgets influence reimbursement strategies.
Q4: Is there potential for price reductions in the foreseeable future?
A4: Not likely, absent new competition or significant policy shifts; high manufacturing costs support stable pricing.
Q5: What is the expected impact of new gene therapies for SMA?
A5: In the short term, competition may marginally impact market share and prices, but current therapies retain dominant positions.
References
- FDA. (2019). Zolgensma (onasemnogene abeparvovec-xioi) approval letter.
- Novartis. (2022). Zolgensma product information.
- IQVIA. (2022). Global SMA market forecast.
- NICE. (2021). Assessment of gene therapy pricing and reimbursement.
- Statista. (2022). Gene therapy market size and projections.
